Effect of Nintedanib on Lung Function in Patients With Systemic Sclerosis−Associated Interstitial Lung Disease: Further Analyses of a Randomized, Double‐Blind, Placebo‐Controlled Trial

Objective In the SENSCIS trial in subjects with systemic sclerosis–associated interstitial lung disease (SSc‐ILD), nintedanib reduced the rate of decline in forced vital capacity (FVC) over 52 weeks by 44% versus placebo. This study was undertaken to investigate the effects of nintedanib on categori...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Arthritis & rheumatology (Hoboken, N.J.) Ročník 73; číslo 4; s. 671 - 676
Hlavní autoři:	Maher, Toby M., Mayes, Maureen D., Kreuter, Michael, Volkmann, Elizabeth R., Aringer, Martin, Castellvi, Ivan, Cutolo, Maurizio, Stock, Christian, Schoof, Nils, Alves, Margarida, Raghu, Ganesh
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States Wiley Subscription Services, Inc 01.04.2021 John Wiley and Sons Inc
Témata:	Adult Aged Confidence intervals Death Disease Progression Double-Blind Method Double-blind studies Female Full Length Humans Indoles - pharmacology Indoles - therapeutic use Lung - drug effects Lung - physiopathology Lung diseases Lung Diseases, Interstitial - drug therapy Lung Diseases, Interstitial - etiology Lung Diseases, Interstitial - physiopathology Male Middle Aged Mortality Placebos Protein Kinase Inhibitors - pharmacology Protein Kinase Inhibitors - therapeutic use Respiratory function Scleroderma Scleroderma, Systemic - complications Scleroderma, Systemic - physiopathology Systemic Sclerosis Treatment Outcome
ISSN:	2326-5191, 2326-5205, 2326-5205
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!